Association of Body Mass Index with Serum Vitamin D and PSA Levels among Sudanese Prostate Cancer Patients
Background: Prostate cancer is the second most common cancer in men worldwide and the second leading cause of cancer deaths in men in the United States. Obesity has been consistently associated with lower 25-hydroxyvitamin D (25(OH)D) concentrations.
Objectives: This cross-sectional study aimed to evaluate the serum vitamin D and PSA levels in Sudanese Obese and Non-Obese prostate cancer (PCa) attending the National Cancer Institute.
Patients and Methods: Eighty six prostate cancer patients were included in this study, they were identified by clinical examination, histopathology and prostate-specific antigen (PSA). The mean age of them was 71.78 ± 8.04 years. Serum Vitamin D and PSA were measured by Electrochemiluminescence (ECL) immunoassay reactions using (Cobase411, serial No: 0868-16, manufactured by Hitachi high technologies corporation, Tokyo-Japan) the Elecsys reagents kit (Roche – Germany)
Results: The means of serum vitamin D levels of among obese was 35.5 ± 15.4 ng/dL and 38.4 ± 16.2 ng/dL among non-obese group with non-significant differences(P=0.505). No signiﬁcant association was observed between PSA levels and obese and non-obese (P=0.351). Vitamin D levels non-significantly negative correlated with BMI (r = -0.031, P = 0.778) and PSA (r = -0.062, P = 0.569), but there was insignificantly Positive correlated between PSA and vitamin D level (r = 0.151, P = 0.164).
Conclusion: insignificant differences between vitamin D and serum PSA with BMI, Oral supplementation is recommended for individuals with low level of vitamin D.
Keywords: Prostate cancer, Body mass index, Vitamin D, PSA, Sudanese.
2- Rashid M, Shamshavali K, Chhabra M. Efficacy and Safety of Nilutamide in Patients with Metastatic Prostate Cancer who Underwent Orchiectomy: A Systematic Review and Metaanalysis. CurrClinPharmacol. 2019; 14(2):108-115. https://doi.org/10.2174/1574884714666190112151202
3- Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009; 9:88. Published 2009 Mar 25. https://doi.org/10.1186/1471-2458-9-88
4- Faith MS, Butryn M, Wadden TA, Fabricatore A, Nguyen AM, Heymsfield SB. Evidence for prospective associations among depression and obesity in population-based studies. Obes Rev. 2011; 12(5):e438-e453. https://doi.org/10.1111/j.1467-789X.2010.00843.x
5- Truesdale KP, Stevens J, Lewis CE, Schreiner PJ, Loria CM, Cai J. Changes in risk factors for cardiovascular disease by baseline weight status in young adults who maintain or gain weight over 15 years: the CARDIA study. Int J Obes (Lond). 2006; 30(9):1397-1407. https://doi.org/10.1038/sj.ijo.0803307
6- Parikh NI, Pencina MJ, Wang TJ, et al. Increasing trends in incidence of overweight and obesity over 5 decades. Am J Med. 2007; 120(3):242-250. https://doi.org/10.1016/j.amjmed.2006.06.004
7- Zhao R, Cheng G, Wang B, et al. BMI and serum lipid parameters predict increasing risk and aggressive prostate cancer in Chinese people. Oncotarget. 2017; 8(39):66051-66060. Published 2017 Aug 2. https://doi.org/10.18632/oncotarget.19790
8- Albertsen PC. Prostate cancer screening and treatment: where have we come from and where are we going?. BJU Int. 2020; 126(2):218-224. https://doi.org/10.1111/bju.15153
9- Freedland SJ, Wen J, Wuerstle M, et al. Obesity is a significant risk factor for prostate cancer at the time of biopsy. Urology. 2008; 72(5):1102-1105. https://doi.org/10.1016/j.urology.2008.05.044
10- Seo DH, Yoon S, Choi JH, et al. The Correlation between Body Mass Index and Routine Parameters in Men Over Fifty. World J Mens Health. 2017; 35(3):178-185. https://doi.org/10.5534/wjmh.16032
11- TAHA, S. M., WENG, H.-Y., MOHAMMED, M. E. I., OSMAN, Y. M., N'DRI, N. S., MOHAMMED, S. I. & ABUIDRIS, D. O. 2020. Prostate cancer clinical characteristics and outcomes in Central Sudan. ecancermedicalscience, 14. https://doi.org/10.3332/ecancer.2020.1116
12- Elgasim, M. A. E. A., Suleiman, Y., Ahmed ELmubark, E. M. E., Abdalmahmoud, A. A. A., Babkeir, S. A. M., Omer, R., Yasin, R., Abaker, K. E. A., Babker, R. O. A., Alryah, A., &Alzain, T. Benefits of Docetaxel for Metastatic Castration-Resistant Prostate Cancer Sudanese Patients and the Effective Number of Cycle and Dose (2013-2017). International Research Journal of Oncology, 2019; 2(2):1-9. Retrieved from https://journalirjo.com/index.php/IRJO/article/view/30100.
13- Abu El Maaty MA, Alborzinia H, Khan SJ, Büttner M, Wölfl S. 1,25(OH)2D3 disrupts glucose metabolism in prostate cancer cells leading to a truncation of the TCA cycle and inhibition of TXNIP expression. BiochimBiophysActaMol Cell Res. 2017 Oct; 1864(10):1618-1630. https://doi.org/10.1016/j.bbamcr.2017.06.019
14- Gorish BM, Ournasseir ME, Shammat IM. Effect of Age, Geographical Affiliation and Environmental Factors on the Development of Prostate Cancer among Sudanese Patients. J Carcinog Mutagen. 2019; 10(3):pp(337).
15- Jungert A, Neuhäuser-Berthold M. Cross-sectional and longitudinal associations between serum 25 hydroxyvitamin D and anti-oxidative status in older adults. ExpGerontol. 2018 Sep; 110:291-297. https://doi.org/10.1016/j.exger.2018.06.024
16- Datta M, Schwartz GG. Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review. Oncologist. 2012; 17(9):1171-9. https://doi.org/10.1634/theoncologist.2012-0051
17- Yue L, Ge Y, Wang T, Ge M, Zhang C, Zhang W. The correlation between body mass index and prostatic-related parameters in men 40 years or older in Zhengzhou. Aging Male. 2020; 23(5):483- https://doi.org/10.1080/13685538.2018.1530754
18- Jeong IG, Hwang SS, Kim HK, Ahn H, Kim CS. The association of metabolic syndrome and its components with serum prostate-specific antigen levels in a Korean-screened population. Cancer Epidemiol Biomarkers Prev. 2010; 19(2):371-380. https://doi.org/10.1158/1055-9965.EPI-09-0760
19- Nair-Shalliker V, Bang A, Egger S, et al. Post-treatment levels of plasma 25- and 1,25-dihydroxy vitamin D and mortality in men with aggressive prostate cancer. Sci Rep. 2020; 10(1):7736. Published 2020 May 8. https://doi.org/10.1038/s41598-020-62182-w
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).